- Molecular NameNefazodone
- SynonymNefazodona [Spanish]; Nefazodone Hcl; Nefazodone Hydrochloride; Nefazodonum [Latin]
- Weight470.017
- Drugbank_IDDB01149
- ACS_NO83366-66-9
- Show 3D model
- LogP (experiment)4.95
- LogP (predicted, AB/LogP v2.0)4.61
- pka6.6
- LogD (pH=7, predicted)4.43
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.53
- LogSw (predicted, AB/LogsW2.0)0.06
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors0
- No.of HBond Acceptors7
- No.of Rotatable Bonds10
- TPSA51.62
- StatusFDA approved
- AdministrationN/A
- PharmacologyA psychoactive drug and antidepressant marketed by Bristol-Myers Squibb.
- Absorption_value100.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability20.0
- Protein binding98.4
- Volume of distribution (VD)0.22 to 0.87 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Main metabolic pathways are hydroxylation of ethyl moiety, p-hydroxylation of m-chloro-benzyl moiety and N-demethylation to mCPP and BMY-33604 catalysed by CYP3A4. Minor metabolites (BMs-183695, BMS-183562) were detected with experiments with human liver microomes
- Half lifeDose dependent; nefazodone, 2 to 5 h (at dose of 200 mg twice daily); hydroxynefazodone, 2 to 4 h; desethylhydroxynefazodone, 18 to 33 h; m-chlorophenylpiperazine, 4 to 9 h.
- ExcretionIn urine (55%) and feces (20–30%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A